Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 1, Double-Blind, Randomized, Placebo-Controlled Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PNU-100480 (PF-02341272) After Administration Of Multiple Escalating Oral Doses To Healthy Adult Subjects
Brief Summary: The purpose of this study is to assess the safety, tolerability and pharmacokinetics of multiple doses of PNU-100480 given for 14 or 28 days. Killing activity against the bacterium that causes tuberculosis (TB) will also be measured. The effect of adding an additional tuberculosis (TB) agent (given for 2 days) in addition to PNU-100480 will be evaluated. Linezolid open label to determine activity in whole blood assay (WBA).


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Rifapentine, Moxifloxacin, Pyrazinamide, Isoniazid | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Isoniazid, Rifampin, Pyrazinamide, Ethambutol | Intervention Type: DRUG; Name: Rifapentine, Moxifloxacin, Pyrazinamide, Isoniazid; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Isoniazid, Rifampin, Pyrazinamide, Ethambutol; Assigned to Arm(s): 2
B: Arm Label: Cohort 1; Type: EXPERIMENTAL; Interventions: Drug: PNU-100480, Drug: Placebo | Arm Label: Cohort 2; Type: EXPERIMENTAL; Interventions: Drug: PNU-100480, Drug: Placebo | Arm Label: Cohort 3; Type: EXPERIMENTAL; Interventions: Drug: PNU-100480, Drug: Placebo | Arm Label: Cohort 4; Type: EXPERIMENTAL; Interventions: Drug: PNU-100480, Drug: Placebo | Arm Label: Cohort 5; Type: EXPERIMENTAL; Interventions: Drug: PNU-100480, Drug: Placebo | Arm Label: Cohort 6 (optional); Type: EXPERIMENTAL; Interventions: Drug: PNU-100480, Drug: Placebo | Arm Label: Linezolid Cohort; Type: EXPERIMENTAL; Interventions: Drug: Linezolid | Intervention Type: DRUG; Name: PNU-100480; Assigned to Arm(s): Cohort 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 1 | Intervention Type: DRUG; Name: PNU-100480; Assigned to Arm(s): Cohort 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 2 | Intervention Type: DRUG; Name: PNU-100480; Assigned to Arm(s): Cohort 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 3 | Intervention Type: DRUG; Name: PNU-100480; Assigned to Arm(s): Cohort 4 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 4 | Intervention Type: DRUG; Name: PNU-100480; Assigned to Arm(s): Cohort 5 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 5 | Intervention Type: DRUG; Name: PNU-100480; Assigned to Arm(s): Cohort 6 (optional) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 6 (optional) | Intervention Type: DRUG; Name: Linezolid; Assigned to Arm(s): Linezolid Cohort
C: Arm Label: Arm 1 (R35); Type: EXPERIMENTAL; Interventions: Drug: Rifampicin, Drug: isoniazid, Drug: pyrazinamide, Drug: ethambutol, Dietary Supplement: pyridoxine | Arm Label: HRZQ; Type: EXPERIMENTAL; Interventions: Drug: SQ109, Drug: Rifampicin, Drug: isoniazid, Drug: pyrazinamide, Dietary Supplement: pyridoxine | Arm Label: HR20ZQ; Type: EXPERIMENTAL; Interventions: Drug: SQ109, Drug: Rifampicin, Drug: isoniazid, Drug: pyrazinamide, Dietary Supplement: pyridoxine | Arm Label: HR20ZM; Type: EXPERIMENTAL; Interventions: Drug: Rifampicin, Drug: isoniazid, Drug: pyrazinamide, Dietary Supplement: pyridoxine | Arm Label: HRZE; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rifampicin, Drug: Moxifloxacin, Drug: isoniazid, Drug: pyrazinamide, Drug: ethambutol, Dietary Supplement: pyridoxine | Intervention Type: DRUG; Name: SQ109; Assigned to Arm(s): HR20ZQ, HRZQ | Intervention Type: DRUG; Name: Rifampicin; Assigned to Arm(s): Arm 1 (R35), HR20ZM, HR20ZQ, HRZE, HRZQ | Intervention Type: DRUG; Name: Moxifloxacin; Assigned to Arm(s): HRZE | Intervention Type: DRUG; Name: isoniazid; Assigned to Arm(s): Arm 1 (R35), HR20ZM, HR20ZQ, HRZE, HRZQ | Intervention Type: DRUG; Name: pyrazinamide; Assigned to Arm(s): Arm 1 (R35), HR20ZM, HR20ZQ, HRZE, HRZQ | Intervention Type: DRUG; Name: ethambutol; Assigned to Arm(s): Arm 1 (R35), HRZE | Intervention Type: DIETARY_SUPPLEMENT; Name: pyridoxine; Assigned to Arm(s): Arm 1 (R35), HR20ZM, HR20ZQ, HRZE, HRZQ
D: Intervention Type: DRUG; Name: Gatifloxacin combined regimen; Assigned to Arm(s): N/A

Answer: B